Successful treatment of palmoplantar hyperkeratotic psoriasis with a combination of etanercept and alitretinoin

Journal of Clinical and Aesthetic Dermatology

Volumn 4, Issue 4, 2011, Pages

  Meyer, Volker ^a   Goerge, Tobias ^a   Luger, Thomas A ^a   Beissert, Stefan ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; CALCIPOTRIOL; CORTICOSTEROID; EFALIZUMAB; ETANERCEPT; METHOTREXATE;

ADULT; ARTICLE; CASE REPORT; CAUCASIAN; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FINGER; FOOT SOLE; HAND PALM; HUMAN; HYPERTENSION; PALMOPLANTAR KERATODERMA; PSORIASIS; PSORIASIS SEVERITY INDEX; PSORIATIC ARTHRITIS; RELAPSE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 79955570637     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Kumar B, Saraswat A, Kaur I. Palmoplantar lesions in psoriasis: a study of 3,065 patients. Acta Derm Venerol. 2002;82:192-195.
2. Cheng C, Michaels J, Scheinfeld N. Alitretionin: a comprehensive review. Expert Opin Investig Drugs. 2008;17:437-443.
3. Ruzicka T, Larsen FG, Galewicz D, et al. Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial. Arch Dermatol. 2004;140:1453-1459.
4. Xu J, Drew PD. 9-Cis-retinoic acid suppresses inflammatory responses of microglia and astrocytes. J Neuroimmunol. 2006;171:135-144.
5. Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kB pathways. Nat Genetics. 2009;41(2):199-204.
6. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trail. Lancet. 2009;373:633-640.